Cytokines News and Research

Latest Cytokines News and Research

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Idera Pharmaceuticals, Inc. today announced that it has chosen to delay initiating its planned Phase 2 clinical trial of IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study of IMO-2125 in rodents. The Phase 2 clinical trial involves the evaluation of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients.

22 Apr 2011

TRIM5 cellular protein helps rhesus monkeys resist HIV

Thanks to a certain protein, rhesus monkeys are resistant to HIV. Known as TRIM5, the protein prevents the HI virus from multiplying once it has entered the cell. Researchers from the universities of Geneva and Zurich have now discovered the protein's mechanism, as they report in Nature. This also opens up new prospects for fighting HIV in humans.

21 Apr 2011

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (DAVANAT®) to enhance the ability of tumor-specific T-lymphocytes to kill tumor cells.

20 Apr 2011

AMIA honors UTMB professor with Distinguished Paper Award for translational bioinformatics

Suresh Bhavnani, an associate professor of biomedical informatics in the Institute for Translational Sciences at the University of Texas Medical Branch at Galveston, was recently honored for using advanced visual analytical methods to propose a new classification of asthma patients.

19 Apr 2011

Chronic exposure to polluted air can lead to inflammation

Chronic inhalation of polluted air appears to activate a protein that triggers the release of white blood cells, setting off events that lead to widespread inflammation, according to new research in an animal model.

16 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

New treatment improves immune function in 13-year-old with Wiskott-Aldrich syndrome

In a novel approach that works around the gene defect in Wiskott-Aldrich syndrome, an inherited immune deficiency disorder, researchers used an alternative cell signaling pathway to significantly improve immune function in a 13-year-old boy with the disease.

15 Apr 2011

Study shows neutralizing antibodies to C5a protein may prevent heart failure

New research published online in The FASEB Journal details research in rats and mice that offers hope for stopping the devastating, and often fatal, effects of sepsis in humans. In the study, University of Michigan researchers show how neutralizing the effects of a key protein fragment, called C5a, used by the immune system to attract white blood cells may ultimately prevent heart failure.

12 Apr 2011

Scientists identify novel mechanism to control cancer spread

Saint Louis University researchers have identified a novel mechanism to control the traffic of cells and fluid from tissues to lymphatic vessels. It may be possible to harness this mechanism to fight cancer spread from one organ to another organ and improve the effectiveness of vaccines.

11 Apr 2011

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Scientists want to protect the optic nerve when the eye takes a blow on the battlefield or in a car wreck.

7 Apr 2011

TZDs might serve as new agents for addiction treatment

Thiazolidinediones are a class of medications that are commonly prescribed to treat type-2 diabetes, while fibrates are a structurally-related class of medications that are prescribed to modulate lipid levels in both diabetic and non-diabetic patients to help reduce the risk of cardiovascular disease.

6 Apr 2011

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Idera Pharmaceuticals, Inc. today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects.

5 Apr 2011

Techne's R&D Systems acquires Boston Biochem assets

Techne Corporation announced today that as of April 1, 2011, its R&D Systems subsidiary has acquired the assets of Boston Biochem, Inc., a leading developer and manufacturer of innovative ubiquitin-related research products.

4 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

New signaling pathway discovery sheds light on chronic dermatitis

A new signaling pathway, which is important for the regulation of the immune response and inflammation, was discovered by an international team of scientists led by prof Ivan Dikic from the Goethe University, Frankfurt, Germany.

1 Apr 2011

Strong 'innate immunity' effective in chikungunya patients

Chikungunya is transmitted by mosquitoes of the genus Aedes. The disease is spreading in the world and periodically sparks new outbreaks. Africa, Asia, the Indian Ocean and even Southern Europe are now affected.

23 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Digna Biotech and Biotecnol to begin CT-I Phase I trial in healthy volunteers

Digna Biotech and Biotecnol announced today that the Spanish Regulatory Medicine Agency has authorized the start of a Phase I Clinical Trial in healthy volunteers for Cardiotrophin-I.

17 Mar 2011

New study on how epoxyeicosatrienoic acids protect kidneys

Researchers at Georgia Health Sciences University are studying whether inhibiting an enzyme that reduces levels of a protective metabolite could halt the progression of diabetic nephropathy, or kidney disease resulting from diabetes.

16 Mar 2011

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Anacor Pharmaceuticals announced today that it has completed enrollment in its Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

14 Mar 2011

Cytokines News and Research

Latest Cytokines News and Research

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

TRIM5 cellular protein helps rhesus monkeys resist HIV

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

AMIA honors UTMB professor with Distinguished Paper Award for translational bioinformatics

Chronic exposure to polluted air can lead to inflammation

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

New treatment improves immune function in 13-year-old with Wiskott-Aldrich syndrome

Study shows neutralizing antibodies to C5a protein may prevent heart failure

Scientists identify novel mechanism to control cancer spread

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

TZDs might serve as new agents for addiction treatment

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Techne's R&D Systems acquires Boston Biochem assets

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

New signaling pathway discovery sheds light on chronic dermatitis

Strong 'innate immunity' effective in chikungunya patients

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Digna Biotech and Biotecnol to begin CT-I Phase I trial in healthy volunteers

New study on how epoxyeicosatrienoic acids protect kidneys

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cytokines News and Research

Latest Cytokines News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in